Astellas Pharma

El pasado mes de junio hemos estado de celebración: se cumplieron 5 años desde la creación de nuestra división de Patient Centricity, como una función independiente, consolidando nuestro compromiso por ser una compañía verdaderamente centrada en el paciente. Para Astellas, los pacientes están en el centro de todo lo que hacemos, es decir, son nuestra razón de ser. Tanto es así, que nuestro lema es justo ese: PATIENTS ARE WHY.   Pero este compromiso no son solo palabras, sino que se traduce a hechos. Trabajamos incansablemente junto a entidades como Ader Asociación , AEAL, Asociación Española de Afectados por Linfoma, Mieloma y Leucemia, la Alianza General de Pacientes (AGP), Federación Nacional de Asociaciones ALCER, ANCAP. Asociación de Cáncer de Próstata,ASIA - Asociación para la Incontinencia anal, Federación ASEM -Federación Española de Enfermedades Neuromusculares, EUPATI España, Foro Español de Pacientes, FNETH, GEPAC - GRUPO ESPAÑOL DE PACIENTES CON CANCER, Asociación Mácula Retina, Pequeños Superhéroes Asociación, la Asociación Española de Enfermos de Pompe y Plataforma de Organizaciones de Pacientes. A todos vosotros, muchas gracias por dejarnos ser parte de vuestro día a día.   Y, aunque nuestro Mes del Paciente haya finalizado, nuestra acción continúa. Por eso os dejamos con este vídeo en el que hemos preguntado a las asociaciones con las que trabajamos qué les inspira en su trabajo diario.    #AstellasEspaña #PatientCentricity #PATIENTSAREWHY Gaceta Médica

We are thrilled to announce the continued collaboration between Astellas and Patient Advocacy Leaders and Drug Development Industry Network (PALADIN), as well as the launch of the highly anticipated PALADIN Playbook and Resource Repository. This collaboration represents an important milestone in our efforts to advance patient advocacy group (PAG) and industry collaborations, with the ultimate goal of increasing access to life-saving treatments. PALADIN Consortium, in which Astellas is an active participant, plays a pivotal role in establishing more effective relationships between PAGs and biopharmaceutical companies. By developing consensus-based guidelines, training, resources, and competencies, PALADIN aims to optimize collaborations and transform the pace of new medical therapies' development. We are excited about the potential of this collaboration and the impact it will have on relevant stakeholders and the community. Together, we can create meaningful change and drive progress in the industry. Stay tuned for further updates and announcements as we continue this exciting journey with PALADIN. For more information, including PALADIN Playbook and Resource Repository, visit https://lnkd.in/gPk4H8M7. #PatientAdvocacy

Over the past few decades, we’ve seen the gradual improvement in cancer outcomes for patients around the world. As part of this, the emergence of innovation in combination therapies is offering patients with cancer a clinically effective treatment option. However, there are significant challenges that payers, healthcare systems and partners must contend with if we want to ensure timely access to the best care for people affected by cancer. Today marks the launch of a new report ‘A framework for value-aligned pricing of combination therapies,’ commissioned by the Office of Health Economics (OHE) and Astellas. The report calls on the wider healthcare community to turn its attention to a bespoke access model for when a medicine is used in combination. We hope that this will help move us one step closer to a system where patients have access to combination therapies in a fair, timely, and sustainable way. It’s vital that we work together with payers, policymakers and industry leaders. We must act now to ensure we have a reimbursement framework that can enable access to these innovative therapies and move with the times as innovation shifts from singular to multiple treatments. Read the full report at: https://lnkd.in/gFJ-yrdD #Healthcare #Innovation #CombinationTherapy #PatientAccess

We are thrilled to announce that Astellas has been named a winner of the CSO Awards. This esteemed recognition is a testament to the collective efforts of the Information Security team in implementing security projects and initiatives that have demonstrated outstanding business value and thought leadership. The CSO Awards recognize exceptional efforts in addressing challenges from an expanding threat landscape. These projects include new threat detection methods, advancements in cyber analytics, and strategies to combat AI threats, establish zero trust, and ensure data protection. Being recognized among the best in the industry is a great honor for Astellas, showcasing our commitment to innovative security thinking and the true business value it brings to the organization. Congratulations to our entire Information Security team! We look forward to celebrating our success at the CSO Conference & Awards this October.    Read more about the CSO Awards:  https://lnkd.in/gfH-PJUH Nick Eshkenazi Jeff Pearl   #InformationSecurity #CyberSecurity #Innovation #CSOConference

As Astellas’ Patient Centricity Month comes to a close, we are excited for where our commitment to prioritizing patients will take us next.  We will continue to learn from new patient perspectives to shape our medicines development. We will also continue to build our work around our ‘PATIENTS ARE WHY™’ purpose.  Thank you to all who joined us this month, and here's to a future filled with patient-centered innovation! Naoki Okamura #PatientCentricityMonth2024 #PATIENTSAREWHY

Geographic atrophy can progress without warning, causing permanent vision loss and blindness. If you or a loved one are over the age of 55, scheduling regular eye exams has never been more important for early detection and intervention that may help maintain your sight for longer. Learn more about the importance of early detection: bit.ly/4bFNX3y #GeographicAtrophy #Ophthalmology #EyeHealth

The unprecedented growth of medical information brings new insight to long-held health challenges and breakthrough patient solutions – and means Medical Affairs teams must play an increasingly strategic and dynamic role.      Executive Vice President and Head of Medical Affairs, Shontelle Dodson, recently shared her perspectives with Clinical Leader on how the field is evolving in today’s innovation landscape – check it out: https://bit.ly/3VsyzSB      #ChangingTomorrow #ScienceFirstForPatients

June is our Patient Centricity Month, where we shine a light on how and why we put patients at the heart of all that we do. Astellas’ Patient Centricity Function was set up in 2019, and in the five years since then, we have:  ✓ Created 5 Patient Centricity (PAT-C) Functional Unit teams.  ✓ Defined the essential operational and cultural components for achieving our patient centricity vision.  ✓ Included Patient Centricity in our 2021 Corporate Strategic Plan.  ✓ Committed to our annual Patient Centricity Month.  ✓ Launched the Patient Centricity Solve-a-Thon, where employees can turn their ideas into real patient solutions.  ✓ Launched the PATIENTS ARE WHY™ brand to unite our patient centric activities.  ✓ Won the Reuters Patient Champion Award, which recognized our actions to bring patient insights into our culture.  ✓ Established Patient Centricity University, a learning hub to make our work more patient centric.  ✓ Delivered our first Patient Partnerships Annual Report.   ✓ Embedded a patient centric culture across all business functions. Looking ahead to the next five years, we hope every company and stakeholder will be focused on what matters most to patients. We are working to help other pharma companies adopt our approach. We will also use our experience to help drive change across entire healthcare systems.  Find out more about Patient Centricity at Astellas: https://lnkd.in/g8Sj8AGb #PatientCentricityMonth2024 #PATIENTSAREWHY

We are thrilled to share that we have joined as a Band A Member of the International Agency for the Prevention of Blindness (IAPB). Together, we will focus on raising awareness, supporting research, strengthening eye health systems and collaborating to tackle the global burden of avoidable sight loss. Learn more about our partnership and this significant step forward in the fight for better eye health for all: bit.ly/3z18Sja #VisionLoss #EyeHealth #Ophthamology

To achieve Astellas’ ambitious carbon reduction goals, it is imperative that we work with our key partners to raise the level of transparency and identify opportunities for innovation. In this spirit of collaboration, we are excited to announce the first-ever Astellas Sustainable Business Partner Summit taking place on June 26. As part of this dynamic forum, Astellas Executive Leadership will share expectations for key partners and the critical role they play in our sustainability journey. With messaging delivered by Adam Pearson (Chief Strategy Officer), Shingo Iino, Ph.D. (Head of Sustainability) and Paul O'Neill (Head of Global Procurement), this event is sure to raise awareness and generate alignment around our efforts to drive significant environmental impact. Our ambitious carbon reduction goals include a 37.5% decrease in Scope 3 GHG emissions by 2030 and Net Zero by 2050. Learn more:  https://lnkd.in/gmHCBUMj Please reach out to supplier.collaboration@astellas.com with any inquiries.